Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach K W
Institute of Health Economics and Clinical Epidemiology of the University of Cologne, Gleueler Str. 176-178, 50935 Cologne, Germany.
Eur Respir J. 2005 Jan;25(1):47-53. doi: 10.1183/09031936.04.00116203.
The purpose of this study was to estimate the prevalence and cost of illness of asthma in Germany by retrospectively analysing routine health insurance data. This analysis investigated claims data from all insured persons of six large sickness funds. Insurants with asthma were identified via the International Classification of Diseases (ninth revision) diagnosis and the Anatomical Therapeutic Chemical Classification System Code for regular medication prescriptions. Costs for hospital care, medication and sick benefit were taken from claims data. Costs for rehabilitation, premature death and early retirement were estimated using the human capital approach and data from national statistics. Prevalence of asthma in the German statutory health insurance was 6.34%. Total costs for asthma, including direct and indirect costs, were calculated at euro 2.74 billion during 1999. The prevalence of asthma in the German statutory health insurance has previously been estimated to be 4-6%. The results of this large study show the prevalence of asthma in the German social insurance system to be approximately 6%. The study also indicates that there is room for substantial savings in the German social insurance system, with indirect costs amounting to 74.8% of total costs and payment of sick benefits through the sickness funds amounting to 58.3% of indirect costs. These costs may be reduced with better asthma control in patients.
本研究的目的是通过回顾性分析常规医疗保险数据，估算德国哮喘的患病率和疾病成本。该分析调查了六大疾病基金所有参保人员的理赔数据。通过国际疾病分类（第九版）诊断和常规药物处方的解剖治疗化学分类系统代码来识别哮喘患者。住院护理、药物治疗和病假津贴的费用取自理赔数据。康复、过早死亡和提前退休的费用采用人力资本法并根据国家统计数据进行估算。德国法定医疗保险中哮喘的患病率为6.34%。1999年哮喘的总成本，包括直接成本和间接成本，计算为27.4亿欧元。此前估计德国法定医疗保险中哮喘的患病率为4%-6%。这项大型研究的结果表明，德国社会保险系统中哮喘的患病率约为6%。该研究还表明，德国社会保险系统有大幅节省成本的空间，间接成本占总成本的74.8%，通过疾病基金支付的病假津贴占间接成本的58.3%。通过更好地控制患者的哮喘，这些成本可能会降低。
